# 9-ING-41 in Patients With Advanced Cancers

Source: https://onco.cc/trials/nct03678883/  
OnCo record `nct03678883` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine, Doxorubicin, Pegylated liposomal doxorubicin in hodgkin lymphoma and non-hodgkin lymphoma, run by Actuate Therapeutics Inc., active and no longer recruiting.

## Summary

9-ING-41 in Patients With Advanced Cancers is a phase 2 interventional study registered as NCT03678883 by Actuate Therapeutics Inc., with 350 participants planned, started 2019-01-04 and due to reach its primary completion in 2026-06. Interventions recorded: 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin.. Conditions listed: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03678883
- Phase: 2
- Setting: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
- Sponsor: Actuate Therapeutics Inc.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT03678883: https://clinicaltrials.gov/study/NCT03678883

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Lomustine (CCNU)](https://onco.cc/drugs/lomustine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/)

---
JSON: https://onco.cc/api/v1/entities/nct03678883.json